Last reviewed · How we verify

NCT04023825: Suprazyg

Analgesic Contribution of the Suprazygomatic Maxillary Nerve Block for Cleft Palate Surgery in Children

Withdrawn NA Last updated 23 March 2023
What this trial tests

NA trial testing suprazygomatic maxillary nerve block in Cleft Palate. Withdrawn.

Timeline
1 July 2019
Primary endpoint
1 July 2022
1 July 2022

Quick facts

Lead sponsorCentre Hospitalier Universitaire, Amiens
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Start date1 July 2019
Primary completion1 July 2022
Estimated completion1 July 2022

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

Adults 5 Months to 12, any sex, with Cleft Palate or Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a monocentric prospective randomized simple-blind designed study evaluating the superiority of the suprazygomatic maxillary nerve block in analgesia after cleft palate surgery compared with a control group. Every two hours, nurses systematically reassess the patient's pain and adjust the analgesic medications. Analgesic requirement, incidence of respiratory complications, re-feeding time and the duration of hospitalization are evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cleft Palate

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04023825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing